Grifols, a global healthcare company, listed as big biotech and big pharma company aims to improve health and well-being of the people. Analysis of the deals since 2005 shows partnering in the areas of hematology, respiratory and hospital care. The three main R&D focus being bioscience, diagnostic and hospital drives the company to produce products of vital importance to improve the quality of life of patients.
The number of partnering, collaborative R&D and licensing deals announced since 2005 stands at 20 partnering deals that covers licensing, collaboration, asset purchase, marketing and so on.
The following figure shows the level of Grifols partnering deal announcements since 2005. The last few years has seen steady levels of partnering activity with 4 deals announced on an average since 2008. However no partnering deals were announced in the year 2012, with an exception of the company buying 51% stake in Araclon Biotech
Figure 1: Grifols partnering deals 2005-2013
Source: Current Agreements, 2013
Analysis of the partnering deals shows a strong emphasis on partnerships in areas of hematology, respiratory and hospital care.
The following table provides an overview of the partnering deals announced by Grifols based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Agreements with Grifols 2005-2013
Figure 2: Grifols partnering deals by therapy area 2005-2013
Source: Current Agreements, 2013
Further analysis of these deals shows that Grifols has a preference for distribution deals. Grifols operates as a fully integrated company with a strong R&D focus and partners to distribute its products through several channels similar to many other top pharmaceutical or big pharma companies.
The following table provides an overview of the partnering deals announced by Grifols based on deal type disclosed.
Figure 3: Grifols partnering deals by deal type 2005-2013
Source: Current Agreements, 2013
When looking at stage of development at partnering deal signing, the most popular stage at signing is marketed stage with 8 deal announcements since 2005. Grifol, in common with many other top pharmaceutical companies, participates in marketed stage deals for the optimal commercialization of their product portfolio.
The following table provides an overview of the partnering deals announced by Grifols based on stage of development at signature.
Figure 4: Grifols partnering by stage of development 2005-2013
Source: Current Agreements, 2013
Grifols has signed over 20 partnering and licensing deals since 2005. The following provides two of the top deals by headline value signed by Grifols
Figure 5: Top Grifols partnering deals by headline value 2005-2013
Figure 5: Top Grifols partnering deals by headline value 2005-2013
Source: Current Agreements, 2013
Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Grifols 2005-2013
Grifols partnering at Current Agreements
View all partnering deals for Grifols: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Partnering Agreements with Grifols 2005-2013
More
Summary profile data for Grifols
Partnering Interests for Grifols
Available reports from Current Partnering
Report: Partnering Agreements with Grifols 2005-2013
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Available resources for deal coverage for Grifols
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on Grifols company profile, recent partnering, M&A and financing news and articles
Related
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
